HealthManagement, Volume 16 - Issue 1, 2016
As the biggest independent provider of advanced diagnostic imaging services in Europe, Affidea owns and operates 170 medical centres and grows at a rate of (on average) one new centre every fortnight.
As the company
evolves, our owners Waypoint Capital want to turn it into the biggest global
brand for diagnostic imaging and cancer care. The cornerstone of doing this is
to introduce practices that are standardised, unified and optimised, but that
respect local cultures and remain patient centric. This becomes increasingly
complex given the sheer number of geographies that Affidea operates in, as well
as the vast amount of data that is accrued on a daily basis. Some of these data
come from the Affidea dose excellence programme through which we currently
centralise and analyse the information extracted from 65,000 computed
tomography (CT) scans each month.
Setting Up The Dose
Excellence Programme
Our dose excellence
programme has been running for several years under the leadership of Katia
Katsari and her team; it incrementally evolves - adapting and learning from
each country as it is introduced.
The foundation of the programme was our initial cooperation
with GE Healthcare in 2012 on the DoseWatch™ analytics platform. This allowed
us to extract the radiation exposure data (as well as other data) from the CT scans performed at our centre in the University Hospital of Szeged, Hungary.
The GE DoseWatch™ system is an excellent tool, but like all
tools, it must be used within a system by knowledgeable individuals for the
full benefits to be realised – implementation, learning and subsequent action
are critical. Having the dose data is great, but fundamentally insufficient
without benchmarking it to the regional guidelines and being able to influence
the subsequent imaging based not only on dose, but also image quality. The dose
excellence programme set out to turn dose awareness and optimisation into a
habit, rather than something that ‘just had to be done’.
After the first installation of DoseWatch™ in 2012, a
further 15 licenses were purchased in 2013. Then in March 2014, a memorandum of
understanding was signed between Affidea and GE for 30 more licenses. In May of
2014, the Affidea dose excellence programme was officially launched.
At first there was a lot of cultural resistance to change. However, this is not unusual in the medical profession, where having an evidence base is absolutely critical to underpin any new initiatives. It came down to communication. A multi-disciplinary steering committee was set up that was able to clearly outline the strategy, process and goals.
Within each country, and within each centre of that country, we have a named radiologist, radiographer and radiation physicist responsible for the dose excellence programme. They work together closely to push it forward in close collaboration with the regional GE DoseWatch™ teams.
Comparing Analytics
Across Vendors
GE Healthcare were early implementers of tracking and
analysing software in CT; they also had the foresight of making the platform
vendor neutral, meaning that we are now able to compare dose data not only
between different models of CT but also different manufacturers using different
dose reduction algorithms. However, before this takes place we have to be
certain that we are comparing ‘like with like’. An initial part of our dose
excellence programme was establishing standardised CT protocols – categorised
by anatomic area and clinical indication across all vendors. We currently have
65 standardised protocols that include information not only on how the scan is
acquired, but also the third percentile dose reference levels (DRL) that
benchmark the radiation dose to the standards. This is another important point
- there are no pan-European standards currently available so we have had to
develop our own specific ‘Affidea standard’ that can encompass all the
variables.
As well as standardised inputs and measuring, the processes
also have to be uniform across each country. Thus, we created Affidea standard
operating procedures and guidelines for the comprehensive implementation of the
programme. These include quality control, mapping and how to implement changes.
Calibration of CT systems is standardised across the whole network.
All doctors work to the best of their ability and are very
keen to show you what they do. Radiologists (I am one) like to show nice
images: ‘Look at the great pictures we are getting and the great diagnostic
capability they give us’. The problem is that without insight into the data,
and some idea of the regional benchmark, you can always get nicer pictures by
giving a higher dose. Meanwhile, many CT radiographers want to reduce the dose,
but often this is done in an unstructured manner - the exposure is reduced, the
images become grainier, the radiologist complains and then the exposure
increases again. It is a kind of yo-yo. This is why image quality has to be a
key output of the dose excellence programme. Without incorporating this aspect
of the process, clinicians will not sign up to the process.
The dose-optimised images have to be non-inferior to the
routinely acquired images and we have processes in place to measure image
quality both subjectively (blinded image assessment) and objectively (using
phantoms).
At Affidea, we have the scale of a country with the speed of
an independent company. We don’t have the lethargy of a national body or
government or university, where any change implementation takes months, if not
years. We also have the expertise of being a specialist high-end diagnostic
imaging provider and this is what we do.
On a monthly basis, we upload all the data from all the
servers onto our central system. We extract all the data and we export the
metadata.
This is important - we don’t export individual patient data,
just the homogenised group data to avoid patient confidentiality and regularity
issues. We have currently networked just over half our install base, and are
already acquiring the data from 65,000 CT scans per month.
Patient Safety Is
Fundamental
The fundamental thing is individual patient safety; this is
the key driver across the whole network. However, given the scale of our
operation we can go from the individual to looking at the imaging trends across
and between whole countries. This also allows dissemination of best practice
and collegiality. For instance, the dose excellence group in Hungary are
collaborating with the dose excellence group in Greece to perform blinded
assessments of each others’ optimised images.
Then there is a comparison between technology and vendor so
we can compare Siemens to Philips to GE. We can look at energy use, effect of
dose reduction algorithms and even the effect that dose optimisation has on the
working lifespan of the x-ray tube.
Despite the focus on standardisation and unification of
pathways and processes, we do not forget that medicine remains an art, and that
to have a truly patient-centred approach there must be nuances in delivery of
care. One size does not fit all, but understanding and justifying variance
allows outliers (by whatever measurement) to be scrutinised. It has been the
experience of the dose excellence programme that clinicians respond where
negative variance can be demonstrated, and solutions offered to improve
practice. Having a high radiation dose scan does not cause censure where it can
be justified on reasonable clinical grounds. Thus, the system becomes one that
everyone feels happy to engage with.
Conclusion
As far as we know, the Affidea dose excellence is the
largest dose optimisation programme of its kind. We have shown that with the
correct processes, standards and engagement with staff it is possible to take
an analytic tool and make it a powerful agent for change.
It is true that ‘you can’t manage what you can’t measure’,
but once the correct analytic tool has been developed, measurement becomes relatively
straightforward. More complex is the choice of data to focus on, and the
management processes used to influence and implement change.